View Cart  

U.S. FDA Draft Guidance Lays Out Time Clock Strategies for PMAs, 510(k)s

A A
The U.S. Food and Drug Administration (FDA) has released updated guidance describing how it intends to comply with submission review timelines set during user fee negotiations earlier this year.

To View This Article:

Login

Subscribe To International Medical Device Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00